Biotech ETF Rises 17% in a Month Without NVIDIA
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
This intro covers scenarios where a price-weighted index may be appropriate and how it contrasts with alternative indexing methods.
22,551 articlesA biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
Three ETFs have stood out in 2026 by delivering positive returns while the S&P 500 retreats. RSP, NLR, and VXUS are t...
A $10,000 investment in Asia’s biggest stocks grew to $15,267 by June 3, 2026, outpacing most U.S. large caps and hig...
Is a recession priced into market? This guide breaks down what pricing in expectations really means, the data to watc...
After a short three-day drift, major averages regained their footing on Thursday. The Dow, S&P 500, and NASDAQ logged...
Investors debating IHE vs XBI face a trade-off between stability and growth. This guide breaks down how ishares pharm...
Market swings push many investors toward complexity. This article reveals a simple, cost-efficient core holding: a Va...
Defensive investing hinges on the right exposure. This guide compares Fidelity FSTA and iShares IYK to answer which b...
SPYM has crossed the $150 billion mark in assets under management, underscoring a shift toward low-cost, broad-market...
Three growth-focused ETFs have fallen this month as rates move and leadership shifts unsettle risk assets. One fund s...
A little-known micro-market has outpaced the broader S&P 500 by roughly fivefold in 30 days, highlighting AI hardware...
Investors are weighing two value plays: VLUE leans on the value factor itself, while VTV sticks with mega-cap, discou...